Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: khrnyc who wrote (2120)	1/29/1998 4:08:00 AM
From: Bill Wexler	Respond to of 7041

Hi Keith. You have STILL failed to answer a very simple question: In post #1880 on Jan 21, you stated: << I do not have any affiliation with ZONA, although after proper due diligence I presently hold a long position in the company.>> Then, in post #1928 on Jan 21, you stated: <<To be more clear, Vasomax is a rapidly dissolving tablet containing the active ingrediant phentolamine. It is not a pill that is swallowed. To my understanding, the tablet is placed in the mouth with some water and dissolves rapidly so that it can then be readily absorbed by the oral mucosa.>> Finally, in post #1986 on Jan 23, you stated: <<Contrary to my posting #1928, vasomax is in fact a pill which is swallowed. It is "an oral formulation which comprises in combination, a vasodilator agent in a rapidly dissolving tablet." I apologize to those of you who I unintentionally led to believe otherwise.>> Here's what I don't understand Keith, so maybe you can help me out here... You claim to be a physician who after "proper due diligence" decided to plunk money down on Zonagen stock. Forgive me for being a bit skeptical and cynical, but how is it that you didn't know at this late date that Vasomax is a pill that is swallowed? In fact, you went to great lengths describing the worthless patent before realizing that you were caught in a lie. I've seen a lot of stock scams. Some of these companies did excellent jobs in deceiving investors for long periods of time before their frauds were uncovered. However, in Zonagen's case, I would say that this is one of the sloppiest, most amateurish con-jobs I have ever seen. In one of my earlier posts I stated that one of the key mistakes Joe Podolski made when engineering this fraud was that he didn't spend enough money on better shills. Now you know why. Zonagen is a fraud and a scam, and Joe Podolski is a filthy crook

To: khrnyc who wrote (2120)	1/29/1998 4:23:00 AM
From: Bill Wexler	Read Replies (2) \| Respond to of 7041

Keith. I re-read your post carefully, and something else struck me as quite odd. It was the last two paragraphs: <<These fluctuations in stock price are irrelevent. At the end of the day what will matter is whether or not Zona has a product, patent protection, and the ability to market their product in light of the competition. In my opinion they have all three; and their tiny current market cap is going to allow those well informed investors to profit out of the present confusion.>> The only thing that's missing is a little touch-up work by a proofreader. Keith, this sounds like the type of shillspeak that pops up on the fax machines of dozens of fund managers and other potential suckers every morning. Keith, are you absolutely certain that if I started to do a little digging, I would find no connection between Keith Rubin (or whoever you really are) and Zonagen?

To: khrnyc who wrote (2120)	1/29/1998 10:52:00 AM
From: Tokyo VD	Respond to of 7041

Keith, While you have provided the lead author and the citation in Journal of Urology, you didn't tell everyone who presented the data at the AUA (that's right you weren't there). BTW, no one was impressed (they were too busy reading the Vivus posters). Dr. Christian Stief, Zonagen clinician/investigator, presented this data. It was based on a subset of 44 patients that Dr. Stief, et al, saw during the failed Phase II studies. In fact, Dr. Stief demonstrated remarkable results in the his patients had higher outcomes and lower placebo rates than the rest of the trial (the other 133 patients). You failed to mention that Dr. Stief also said that "further studies have to corroborate our results" (given that the trial failed to demonstrate a statistically significant p-value, I'd say Zonagen has some answering to do). Years earlier, Dr. Stief was the doctor who reported that only 1 of 15 patients was able to obtain an erection from a phentolamine injection. Tokyo